Mr. Ian Campbell reports

NEURAL PORTFOLIO COMPANY HANF.COM EXPANDS GERMAN RETAIL FOOTPRINT WITH NEW MUHLDORF AM INN STORE AND FOUR REFURBISHED LOCATIONS

Neural Therapeutics Inc., together with its portfolio company CWE European Holdings Inc., operating as Hanf.com, one of Germany's leading cannabidiol retailers, has opened a new Hanf.com retail store in Muhldorf am Inn, Germany, and has made continuing refurbishment initiatives across selected existing Hanf.com locations.

The new Muhldorf am Inn store is located at Stadtplatz 76, 84453 Muhldorf am Inn, Germany, in the historic town centre. The location expands Hanf.com's retail presence into another smaller regional market and is intended to support the company's broader strategy of disciplined retail growth across Germany.

Ronnie Jaegermann, chief executive officer of CWE European Holding, stated: "Over the past six months, Hanf.com has continued to demonstrate that our retail platform is not standing still. Although Muhldorf is a smaller town, the store experienced a warm welcome from the local community. The performance of this opening reinforces our view that smaller towns can offer compelling opportunities as customer awareness can be built more quickly and local market penetration may be achieved more efficiently than in larger urban centres."

In addition to new store openings, Hanf.com has completed refurbishment work at four existing locations: Straubing, Bavaria; Regensburg, Bavaria; Herford, North Rhine-Westphalia; and Freising, Bavaria. These upgrades were undertaken to improve store presentation, enhance the customer experience and support a more consistent Hanf.com brand standard across the retail network.

Neural believes Hanf.com's continued retail execution supports the strategic rationale for Neural's investment in CWE and provides further evidence of Hanf.com's ability to scale its German retail footprint in a disciplined manner.

About Neural Therapeutics Inc. and CWE European Holdings Inc.

Neural Therapeutics is a leader in ethnobotanical drug discovery focused on developing therapeutic drugs for mental health conditions related to substance use disorders, including alcohol and opioid dependence. The company's innovative drug development strategy involves the use of subhallucinogenic doses of mescaline extract, with the objective of enhancing safety and scalability while maintaining therapeutic efficacy.

On May 26, 2025, Neural entered into a strategic investment and option agreement with CWE European Holdings, a leading CBD and hemp retailer in Germany operating under the Hanf.com brand, pursuant to which Neural may acquire up to 100 per cent of CWE through a multistage transaction. The transaction is intended to expand Neural's commercial footprint in Europe while preserving its core focus on drug discovery and mental health innovation.

On Aug. 12, 2025, Neural and CWE completed the first stage of the transaction, pursuant to which Neural acquired a 30.75-per-cent ownership interest in CWE. Neural and CWE continue to work collaboratively toward subsequent stages of the transaction, and Neural will provide updates as material developments occur.

We seek Safe Harbor.